NCT06763315 (LS-NF1PNs) is a Phase 2 clinical trial of Selumetinib in Plexiform Neurofibromas (PN), sponsored by West China Hospital.

Who is sponsoring NCT06763315?

NCT06763315 is sponsored by West China Hospital.

What drugs are being tested in NCT06763315?

Interventions in NCT06763315: Selumetinib.

What condition does NCT06763315 study?

NCT06763315 studies Plexiform Neurofibromas (PN).

Is NCT06763315 still recruiting?

NCT06763315 is currently not yet recruiting. Last updated 8 January 2025.

Last reviewed 2025-01-08 · How we verify

NCT06763315: LS-NF1PNs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children

Not yet recruiting Phase 2 Last updated 8 January 2025

What this trial tests

Phase 2 trial testing Selumetinib in Plexiform Neurofibromas (PN) in 50 participants. Not yet recruiting.

Timeline

1 January 2025

Primary endpoint
31 January 2028

31 October 2028

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 January 2025
Primary completion	31 January 2028
Estimated completion	31 October 2028
Sites	1 location across China

Drugs / interventions tested

Selumetinib — full drug profile →

Conditions studied

Plexiform Neurofibromas (PN) — all drugs for Plexiform Neurofibromas (PN) →

Sponsor

West China Hospital

Who can join

Adults 3 to 18, any sex, with Plexiform Neurofibromas (PN). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to compare the efficacy and safety of low-dose and internationally recommended standard dose of selumetinib in the treatment of plexiform neurofibromas in Chinese children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Selumetinib

Trials testing the same drug.

NCT06735820 — Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST · Phase 1, PHASE2 · not yet recruiting
NCT06188741 — Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 · Phase 2 · recruiting
NCT06621082 — The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule · Phase 2 · not yet recruiting
NCT06620354 — Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule · Phase 2 · not yet recruiting
NCT05825365 — Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study · Phase 2 · withdrawn

Other recruiting trials for Plexiform Neurofibromas (PN)

Currently open trials in the same condition.

NCT02407405 — MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Pl · Phase 2 · active not recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06763315 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 8 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing